Enovis (NYSE:ENOV) surged about 15% after CMS reversed reimbursement cuts for its noninvasive bone growth stimulators, bouncing back from a prior 12% drop, as Evercore and new BMO coverage both signal positive analyst sentiment for the stock.
Previous Week Recap
- Enovis Shares Jump On CMS Reversal: Enovis (ENOV) shares jumped ~15% after CMS reversed reimbursement cuts for its non‑invasive bone growth stimulators. The move followed a prior session drop of about 12%.
- Enovis Sentiment Upgraded By Brokers: Evercore kept an Outperform on Enovis (ENOV); BMO started coverage with Outperform. Traders: both brokerages signal positive analyst sentiment for ENOV.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.